FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
0001544227
US60040X1037
60040X103
110 Miller Ave Ste 100
17348459000
US
12
Oct 4, 2012
We are unable to load the chart at this time.
0001544227
NASDAQ
Biotechnology
Healthcare
60040X103
US60040X1037
US
1.06
0.48
140.97k
11.15M
-
1.06-1.13
31.42
-
-
-
-
0
-
http://www.millendo.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
GlobeNewsWire
Jun 22, 2021
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”
Business Wire
Apr 7, 2021
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc. pursuant to which Millendo shareholders are expected to only own approximately 18.5% of the combined company, subject to adjustments. KSF is seeking to determine whether the merger and the process that led to it are
PRNewsWire
Apr 2, 2021
NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Millendo Therapeutics, Inc. ("MLND" or the "Company") ( MLND ) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to...
Business Wire
Mar 31, 2021
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. Halper Sadeh encourages Millendo shareholders to click here to
Pulse2
Mar 29, 2021
The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.
Benzinga
Mar 29, 2021
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.
seekingalpha.com
Aug 13, 2020
Yahoo
Aug 10, 2020
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results